## **Truth in Testimony Disclosure Form**

In accordance with Rule XI, clause 2(g)(5)\* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee:				
Subcommittee:				
Hearing Date:				
Hearing :				
Witness Name:				
Position/Title:				
Witness Type: O Governmental O Non-governmental				
Are you representing yourself or an organization? Organization				
If you are representing an organization, please list what entity or entities you are representing:				
FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY				
Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.				
Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any				
organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.				

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.
Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.
Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.
☐ I have attached a written statement of proposed testimony.
☐ I have attached my curriculum vitae or biography.

- (5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.
- (B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include—
  (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.
- (C) The disclosure referred to in subdivision (B)(iii) shall include—(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.
- (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

<sup>\*</sup>Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

False Statements Certification	
Knowingly providing material false information to this committee/subcommittee, or knomaterial information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). The made part of the hearing record.	<i>C</i> ,
Witness signature	Date

Proprietary Information Confidential Treatment Requested February 21, 2021

## Attachment A

U.S. Source	Purpose	Amount
Biomedical Advanced Research	Contract to fund Phase 2 and	Current contract ceiling
and Development Authority	Phase 3 studies for process	is \$954.9 million.
	development/scale up for	
	mRNA-1273	
U.S. Army Contracting	Agreement, with options, to	Current contract ceiling,
Command - Aberdeen Proving	purchase doses of Moderna's	including options
Ground (ACC-APG), Natick	mRNA-1273 vaccine.	exercised to date, is
Division		\$4.84 billion.
National Institutes of	Contract related to Phase 1	\$0
Health/Division of Microbiology	study. Moderna provided	
and Infectious Diseases/National	materials and Division of	
Institute of Allergy and Infectious	Microbiology and Infectious	
Diseases	Diseases performed Phase 1	
	study.	
National Institutes of Health	Contract related to receipt of	\$0
	proteins and plasmids for	
	evaluation and assay	
	development.	
National Institute of Allergy and	Contract related to ongoing	\$0
Infectious Diseases	research collaboration.	
	Amended to include pre-	
	clinical activities related to	
	SARS-CoV2.	